AA
ALDR

ALPS Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

ALPS Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-43,366
Closed -$902K – 798
2017
Q1 		$902K Sell
43,366
-4,968
-10% -$110K 0.01% 227
2016
Q4 		$1M Sell
48,334
-15,644
-24% -$407K 0.01% 218
2016
Q3 		$2.1M Buy
+63,978
New +$1.95M 0.02% 180
2016
Q1 		– Sell
-57,452
Closed -$1.9M – 797
2015
Q4 		$1.9M Sell
57,452
-10,654
-16% -$360K 0.02% 184
2015
Q3 		$2.23M Buy
68,106
+30,477
+81% +$1.3M 0.02% 163
2015
Q2 		$1.99M Buy
37,629
+19,367
+106% +$704K 0.02% 169
2015
Q1 		$527K Buy
+18,262
New +$501K ﹤0.01% 414

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ALPS Advisors's ALDR Position: Q2 2017 in Review

ALPS Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 43,366 shares — an estimated $902K sold.

ALPS Advisors first reported a position in ALDR in Q1 2015 and held it in 7 quarters. The position peaked at $2.23M in Q3 2015. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

  • ALPS Advisors reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • ALPS Advisors sold 43,366 Alder Biopharmaceuticals shares in Q2 2017, an estimated $902K.
  • ALPS Advisors first reported a position in Alder Biopharmaceuticals in Q1 2015 and held it in 7 quarters.
  • ALPS Advisors's Alder Biopharmaceuticals position peaked at $2.23M in Q3 2015.
  • 128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on ALPS Advisors's 13F filing for Q2 2017, filed 3 Aug 2017.